Amryt Pharma (AMYT) Financials

$14.70

$0.00 (0.00%)

As on 21-Apr-2023 09:30EDT

Market cap

$943 Mln

Revenue (TTM)

$244 Mln

P/E Ratio

39.7

P/B Ratio

1.4

Div. Yield

0 %

Annual
Quarterly

Income Statement (€ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-14	Dec-13	Dec-12	Dec-11
Operating Revenue	243.62	222.54	182.61	58.12	16.53	15.33
Cost of Revenue	127.03	106.12	119.03	42.00	6.06	6.45
Gross Profit	116.59	116.42	63.58	16.12	10.47	8.88
Operating Expenses	161.67	138.07	109.02	52.17	27.92	25.93
Operating Profit (EBIT)	3.75	-21.64	-45.44	-36.04	-17.44	-17.04
Other Income	--	--	--	--	--	--
Profit before Tax	-24.61	-29.81	-105.86	-66.76	-29.45	-31.36
Provision for Tax	-4.65	-11.64	-1.33	-1.23	0.04	--
Profit after Tax (Net Income)	-19.96	-18.17	-104.53	-65.54	-29.49	-31.36
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-19.96	-18.17	-104.53	-65.54	-30.49	--

Liabilities (€ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-14	Dec-13	Dec-12	Dec-11
Shareholder's Funds	324.28	337.45	66.14	129.32	-3.70	26.26
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	269.45	288.64	369.27	304.81	72.47	58.07
Current Liabilities	143.14	157.28	101.18	100.21	12.04	11.76
Total Liabilities	880.02	783.37	536.59	534.35	80.81	96.08

Assets (€ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-14	Dec-13	Dec-12	Dec-11
Non-Current Assets	512.43	500.66	333.62	387.11	61.52	64.50
Current Assets	224.45	282.71	202.98	147.24	19.28	31.58
Total Assets	880.02	783.37	536.59	534.35	80.81	96.08
Total Debt*	212.79	199.18	188.39	178.47	19.00	12.72
Net Current Assets	81.30	125.43	101.80	47.03	7.24	19.83

Cashflow (€ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-14	Dec-13	Dec-12	Dec-11
Cash From Operating Activities	--	15.53	26.89	-37.50	-14.95	-14.23
Cash Flow from Investing Activities	--	106.40	-2.38	24.43	-0.23	--
Cash from Financing Activities	--	-125.43	26.03	65.94	3.18	29.21
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-14	Dec-13	Dec-12	Dec-11
Adjusted EPS (€)	-0.20	-0.37	-3.27	--	--	--
Cash EPS (€)	--	0.66	-1.88	--	--	--
Adjusted Book Value (€)	--	6.89	2.07	--	--	--
Dividend per Share (€)	--	--	--	--	--	--
Cash Flow per Share (€)	--	0.32	0.84	--	--	--
Free Cash Flow per Share (€)	--	0.29	0.76	--	--	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-14	Dec-13	Dec-12	Dec-11
ROCE (%)	--	-4.59	-37.18	-40.57	-108.63	-85.06
ROE (%)	-5.96	-9.00	-106.95	-104.33	-261.40	-102.80
ROA (%)	-2.11	-2.75	-19.52	-21.31	-33.34	-38.07
EBIT Margin (%)	1.54	-9.72	-24.89	-62.01	-168.60	-197.94
Net Margin (%)	-8.19	-8.17	-57.24	-112.75	-178.34	-204.54
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-14	Dec-13	Dec-12	Dec-11
Revenue Growth (%)	19.23	0.22	2.14	2.52	0.08	9.79
EBIT Growth (%)	104.14	52.38	-26.08	-29.30	8.13	-269.81
Net Profit Growth (%)	83.08	82.62	-59.50	-122.26	5.96	-282.03
EPS Growth (%)	93.77	0.89	--	--	--	--
Book Value Growth (%)	-12.25	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-14	Dec-13	Dec-12	Dec-11
Debt to Equity	0.64	0.59	2.85	1.38	-5.14	0.48
Short term debt to equity ratio	0.00	--	0.01	--	--	--
Current Ratio	1.57	1.80	2.01	1.47	1.60	2.69
Quick Ratio	0.94	1.06	1.60	1.03	1.42	2.58
Interest Coverage	0.23	-0.78	-2.32	-4.25	-17.76	-30.00

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-14	Dec-13	Dec-12	Dec-11
Debtors to sales (%)	20.86	24.22	23.65	62.60	35.83	37.01
Asset Turnover	0.26	0.34	0.34	0.19	0.19	0.19
Receivable days	--	79.68	79.58	132.94	128.10	99.41
Inventory Days	--	269.78	129.82	198.97	103.54	59.75
Payable days	--	225.95	174.38	125.03	330.68	216.83
Cash Conversion Cycle	--	123.51	35.03	206.88	-99.04	-57.67

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.